Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
Astex Pharmaceuticals, Inc (ASTX)
|
Add to portfolio |
|
|
|
| Price: |
$2.41
| | Metrics |
| OS: |
94.9
|
M
| |
|
% ROE
|
| Market cap: |
$229
|
M
| |
|
% ROIC
|
|
Net cash:
|
$134
|
M
| |
$1.41
|
per share
|
|
EV:
|
$94.9
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($683.0)
|
k
| |
|
|
|
EBIT
|
($9.6)
|
M
| |
|
|
| EPS |
($0.01)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| Revenues | 83.2 | 66.9 | 53.0 | 41.3 | 38.4 | 23.4 | 38.1 | 30.2 |
| Revenue growth | 24.3% | 26.3% | 28.4% | 7.4% | 64.0% | -38.5% | 26.2% | -5.7% |
| Cost of goods sold | -91.5 | -65.2 | -37.8 | 0.0 | 0.0 | 0.2 | 2.0 | 3.1 |
| Gross profit | 174.6 | 132.1 | 90.8 | 41.3 | 38.4 | 23.2 | 36.1 | 27.1 |
| Gross margin | 210.0% | 197.4% | 171.4% | 100.0% | 100.0% | 99.1% | 94.7% | 89.9% |
| Selling, general and administrative | 15.7 | 16.8 | 9.4 | 9.0 | | 13.5 | 24.7 | 28.0 |
| Research and development | 60.4 | 43.9 | 28.4 | 29.7 | | | | |
| General and administrative | | | | | 11.1 | | | |
| EBITA | 8.4 | 6.9 | 15.9 | 2.7 | -0.5 | -3.8 | -5.2 | -16.0 |
| EBITA margin | 10.0% | 10.3% | 30.0% | 6.5% | -1.3% | -16.1% | -13.6% | -53.0% |
| Amortization of intangibles | 8.0 | 3.2 | | 0.1 | 0.4 | | | |
| EBIT | 0.4 | 3.7 | 15.9 | 2.6 | -0.9 | -3.8 | -5.2 | -16.0 |
| EBIT margin | 0.4% | 5.5% | 30.0% | 6.2% | -2.4% | -16.1% | -13.6% | -53.0% |
| Pre-tax income | -4.8 | 2.3 | 16.3 | 3.9 | -9.2 | 0.0 | -15.9 | -14.5 |
| Income taxes | -13.0 | -3.3 | 0.0 | -0.9 | 0.0 | 0.0 | 0.6 | 0.0 |
| Tax rate | 272.4% | | 0.2% | | 0.5% | | | 0.0% |
| Net income | 8.2 | 5.5 | 16.3 | 4.7 | -9.1 | 0.0 | -16.5 | -14.5 |
| Net margin | 9.9% | 8.3% | 30.7% | 11.5% | -23.7% | 0.0% | -43.3% | -48.0% |
| |
| Diluted EPS | $0.08 | $0.07 | $0.27 | $0.08 | ($0.16) | | ($0.31) | ($0.28) |
| Shares outstanding (diluted) | 102.0 | 75.8 | 60.6 | 59.3 | 57.7 | | 53.4 | 51.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|